NanoViricides Inc. (NYSE American: NNVC), a clinical-stage biotechnology company, announced its participation in the Life Science Executive Partnering (LSX) World Congress 2025 in Boston, where it will present its innovative nanoviricide platform technology. The presentation, scheduled for September 17 at 12:30 p.m., will focus on the company's broad-spectrum antiviral drug candidates designed to combat viral escape mechanisms, a critical challenge in antiviral therapy.
The company's lead drug candidate, NV-387, represents a significant advancement in antiviral treatment development. This broad-spectrum antiviral is being developed for multiple respiratory viral infections including RSV, COVID-19, long COVID, influenza, and MPOX/smallpox infections. Another advanced candidate, NV-HHV-1, targets shingles treatment, demonstrating the platform's versatility across different viral families.
NanoViricides' technology platform is based on intellectual property licensed from TheraCour Pharma Inc., with exclusive, sub-licensable field licenses for specific viral applications. The company's business model involves licensing technology from TheraCour Pharma Inc. for targeted antiviral verticals, established since the company's foundation in 2005. This approach allows for focused development against specific viral pathogens while maintaining broad application potential.
The company is developing two distinct COVID-19 drug candidates: NV-CoV-2, which does not encapsulate remdesivir, and NV-CoV-2-R, which incorporates remdesivir within its polymeric micelles. The latter candidate benefits from remdesivir's existing FDA approval, potentially streamlining the regulatory pathway if safety profiles prove comparable. Both candidates were developed independently by NanoViricides.
Beyond respiratory viruses, the company's pipeline includes development programs for oral and genital herpes, viral eye diseases including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus. The platform technology leverages TheraCour's nanomedicine approach, with NanoViricides holding perpetual exclusive licenses for specific viral targets including HIV/AIDS, hepatitis viruses, rabies, herpes viruses, influenza strains, dengue viruses, and coronaviruses.
The company acknowledges the inherent risks in drug development, noting that the path to pharmaceutical product approval is lengthy and capital-intensive. There can be no assurance that laboratory success will translate to effective clinical trials or marketable products. However, the presentation at LSX World Congress 2025 provides an important platform for showcasing this innovative approach to antiviral therapy that addresses the critical issue of viral resistance.
For investors seeking additional information, the company maintains its newsroom at https://ibn.fm/NNVC, providing updates on development progress and corporate announcements. The LSX presentation represents a significant opportunity for the company to demonstrate its technology's potential to pharmaceutical partners and investors in the life sciences community.
